# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM") today announced that an analysis of the complete clinical patient data from the ...
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $5.25 ...
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM") today announced the official print publication of the data analysis from a long-...
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.12) b...
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the successfully completion of cGMP man...